Umecrine Cognition raises new funds to support clinical development of novel drug candidate GR3027 for hepatic encephalopathy - ...
SOLNA, Sweden, March 10, 2016 (GLOBE NEWSWIRE) -- Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company developing a novel treatment for hepatic encephalopathy (HE) in patients with liver disease, today announces it has …